Ocuphire appoints George Magrath as CEO effective Nov 1; awards 1M equity shares

Opus Genetics, Inc.

Dr. George Magrath appointed CEO and board member, effective Nov 1, 2023; succeeds interim CEO Rick Rodgers who remains on board.
Employment agreement: $575,000 base salary, 55% target bonus, 600,000 stock options and 400,000 RSUs as inducement grants.
Inducement plan increased by 2,000,000 shares to total 2,325,258 shares available for equity awards.
Magrath previously CEO of Lexitas Pharmaceutical Services; led acquisition and growth in ophthalmic CRO.
Committee composition changed effective Nov 15: Cam Gallagher chairs audit, James Manuso chairs compensation, Richard Rodgers chairs nominating.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. George Magrath

Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-11-01
Filed: November 1, 2023, 7:59 PM ET

On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. George Magrath was appointed as Chief Executive Officer at Opus Genetics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.

View on SEC.gov

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-050844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.